Cetuximab plus platinum-based chemotherapy in head and neck Squamous Cell Carcinoma: a retrospective study in a single Comprehensive European Cancer Institution by De Mello, Ramon Andrade et al.
Cetuximab Plus Platinum-Based Chemotherapy in Head
and Neck Squamous Cell Carcinoma: A Retrospective
Study in a Single Comprehensive European Cancer
Institution
Ramon Andrade de Mello1,2,3*, Sandra Gero´s4,5, Marcos Pantarotto Alves1, Filipa Moreira3,
Isabel Avezedo1, Jose´ Dinis1
1Department of Medical Oncology, Head and Neck Unit, Portuguese Oncology Institute, Porto, Portugal, 2Department of Medicine and Biomedical Sciences, School of
Medicine, University of Algarve, Faro, Portugal, 3Department of Medicine, Faculty of Medicine, University of Porto, Porto, Portugal, 4 Service of Otorhinolaryngology, Head
and Neck Unit, Portuguese Oncology Institute, Porto, Portugal, 5Department of Otorhinolaryngology and Cervical Facial Surgery, Centro Hospitalar de Vila Nova de Gaia/
Espinho, Vila Nova de Gaia, Portugal
Abstract
Background: The use of cetuximab in combination with platinum (P) plus 5-fluorouracil (F) has previously been
demonstrated to be effective in the treatment of metastatic squamous cell cancer of head and neck (SCCHN). We
investigated the efficacy and outcome of this protocol as a first-line treatment for patients with recurrent or metastatic
disease. We evaluated overall-survival (OS), progression-free-survival (PFS), overall response rate (ORR) and the treatment
toxicity profile in a retrospective cohort.
Patients and Methods: This study enrolled 121 patients with untreated recurrent or metastatic SCCHN. The patients
received PF+ cetuximab every 3 weeks for a maximum of 6 cycles. Patients with stable disease who received PF+ cetuximab
continued to receive cetuximab until disease progressed or unacceptable toxic effects were experienced, whichever
occurred first.
Results: The median patient age was 53 (37–78) years. The patient cohort was 86.8% male. The addition of cetuximab to PF
in the recurrent or metastatic setting provided an OS of 11 months (Confidential Interval, CI, 95%, 8.684–13.316) and PFS of
8 months (CI 95%, 6.051–9.949). The disease control rate was 48.9%, and the ORR was 23.91%. The most common grade 3 or
4 adverse events in the PF+ cetuximab regimen were febrile neutropenia (5.7%), skin rash (3.8%) and mucosistis (3.8%).
Conclusions: The results of this study suggest that cetuximab plus platinum–fluorouracil chemotherapy is a good option for
systemic treatment in advanced SSCHN patients. This regimen has a well-tolerated toxicity profile.
Citation: de Mello RA, Gero´s S, Alves MP, Moreira F, Avezedo I, et al. (2014) Cetuximab Plus Platinum-Based Chemotherapy in Head and Neck Squamous Cell
Carcinoma: A Retrospective Study in a Single Comprehensive European Cancer Institution. PLoS ONE 9(2): e86697. doi:10.1371/journal.pone.0086697
Editor: Apar Kishor Ganti, University of Nebraska Medical Center, United States of America
Received September 16, 2013; Accepted December 11, 2013; Published February 6, 2014
Copyright:  2014 de Mello et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: Ramon Andrade de Mello is an AE for PLOS ONE. However, this does not alter the authors’ adherence to all the PLOS ONE policies on
sharing data and materials.
* E-mail: ramondemello@gmail.com
Introduction
Squamous cell carcinoma of the head and neck (SCCHN),
including the oral cavity, nasopharynx, hypopharynx, larynx and
tongue, is the 5th most common cancer worldwide and represents
4% of all diagnosed neoplasms [1]. The annual world incidence is
approximately 500,000 new cases, and patients with metastatic
disease have very poor outcomes [2]. In Europe, head and neck
tumors account for 139,000 new cases per year [3,4]. Currently,
patients with operable and early-stage disease receive conservative
surgery or radiotherapy as the standard of care. Induction
chemotherapy with TPF (taxane, platinum and fluoropirimidine)
followed by radiotherapy or chemo-radiotherapy is an option for
organ preservation in advanced larynx and hypopharynx patients
otherwise requiring laryngectomy [5]. In the recurrent/metastatic
disease setting, the 5-year OS rate is approximately 39.4% [6].
However, the survival among patients with head and neck cancer
has only modestly improved over the past 30 years [7]. Many
international centers advocate salvage surgery as the primary
option for recurrent SCCHN [7]. However, for patients ineligible
for surgery, platinum-based chemotherapy is the backbone of
treatment [5,8,9]. Many trials have accessed doublet [2,8,10] and
triplet drug [8,11–13] combinations in the recurrent/metastatic
setting and have shown modest outcomes. Epidermal growth
factor receptor (EGFR) pathways were shown in previous pre-
clinical studies to have a major role in SCCHN carcinogenesis by
regulating p53 and Rb gene expression. p53 and Rb are regulators
of cell cycle control, cell proliferation and apoptosis [14,15]. More
PLOS ONE | www.plosone.org 1 February 2014 | Volume 9 | Issue 2 | e86697
recently, cetuximab, an IgG1 monoclonal antibody against the
extracellular portion of the epidermal growth factor receptor
(EGFR), was extensively studied in this field [9,13,16]. Since 2005,
several phase I-III trials [8,11–13] have assessed cetuximab in
combination with standard chemotherapy for the treat of
recurrent/metastatic SCCHN. In 2008, Vermoken et al. [3]
published the results of an interesting phase III trial that showed
improved outcome results with a combination of cetuximab with
platinum plus 5-fluourouracil (5-FU) in the treatment of advanced
SCCHN patients. These results led to the approval of this regimen
in Europe and the United States. Herein, we report the results of a
retrospective study with the primary end-point of assessing
outcomes in a southern European comprehensive cancer institu-
tion. We analyzed overall survival (OS) and progression-free-
survival (PFS) after the addition of cetuxumab to a platinum plus
5-FU regimen. The secondary end-points of this study were the
assessment of treatment related-toxicities and disease control.
Patients and Methods
Design
Our study was conducted from January 2010 to January 2013 at
the Central Comprehensive Cancer Hospital in northern Portugal:
the Portuguese Oncology Institute (IPO-PORTO), Porto, Portu-
gal. The study was approved by the IPO-PORTO’s ethical
committee and was conducted according to the Declaration of
Helsinki. Signed written-informed consent form was obtained
from all patients involved in this study.
Patients
The patient inclusion criteria were the following: confirmed
histologic diagnosis of recurrent/metastatic squamous cell carci-
noma of head and neck, age greater than 18 years, ineligibility for
local therapy, at least one lesion that was bi-dimensionally
measurable by computed tomography (CT), an Eastern Cooper-
ative Oncology Group (ECOG) performance status score of 0–2,
and adequate hematologic, renal, and hepatic function. No tumor
tissue was assessed for EGFR or for human papilloma virus (HPV)
expression. Patients who did not meet the inclusion criteria were
excluded from this study. Other exclusion criteria were surgery or
irradiation within the previous 4 weeks, previous systemic
chemotherapy unless it was part of multimodal treatment for
locally advanced disease that had been completed more than 6
months before study entry, nasopharyngeal carcinoma and other
concomitant anticancer therapies. Data were collected from
clinical records at the participant institution. All patients involved
in this study were Portuguese Caucasians.
Treatment schedule regimen
Selected patients were submitted to systemic treatment with
either cisplatin (at a dose of 100 mg/m2 body-surface area as a 2-
hour intravenous infusion on day 1) or carboplatin (at an area
under the curve of 5 mg per milliliter per minute, as a 1-hour
intravenous infusion on day 1). The patients received an infusion
of fluorouracil (at a dose of 1000 mg/m2 per day for 4 days under
continuous infusion) every 3 weeks for six cycles. The use of
cisplatin or carboplatin was determined according to patient
fitness status and physician discretion. Cetuximab was adminis-
tered at an initial dose of 400 mg/m2 given as a 2-hour
intravenous infusion, followed by subsequent weekly doses of
250 mg/m2 given as a 1-hour intravenous infusion. The
cetuximab infusions ended at least 1 hour before the start of
chemotherapy. After a maximum of six cycles of chemotherapy,
patients who had at least stable disease received cetuximab
monotherapy until disease progression or unacceptable toxicity.
End-points
The primary end-point of our study was overall survival, which
was defined as the period between the date of death/last medical
visit and date of first recurrence/metastasis diagnosis. Progression-
free-survival was defined as the period between the date of second
recurrence/metastasis diagnosis and the date of first recurrence/
metastasis diagnosis. The secondary end-point was overall
response rate (ORR), which included complete response (CR)
and partial response (PR). Responses were defined according to
Response Evaluation Criteria in Solid Tumors (RECIST) [17].
Disease control (ORR+ stable disease) and toxicity profiles were
extracted from clinical records according to the Common
Terminology Criteria for Adverse Events version 4.0. Patients
were considered evaluable for efficacy if they completed at least 3
cycles of treatment per institution protocol analysis. Tumors were
assessed by CT scan at baseline and after 3 cycles of combination
therapy (approximately 12 weeks from the start of therapy). If a
patient did not tolerate the treatment due to grade 3 and 4
toxicities, the main approach was to stop the treatment and select
a second-line treatment if the patient was fit to receive another
treatment. If patients progressed quickly, the treatment was
stopped and the patients were offered alternate treatment options.
Statistical analysis
The chi-squared and Wilcoxon-Mann Whitney tests were used
to compare the frequency distributions of variables such as age,
sex, tumor site, extent of disease, ECOG performance status,
smoking status, histologic type, previous treatment, and Tumor,
Node, Metastasis (TNM) stage classification in the study popula-
tion. We analyzed OS and PFS using a Kaplan-Meier curve. All
statistical tests were two-sided, and p,0.05 was considered the
threshold of statistical significance. All data analyses were
performed using IBMH SPSS Statistics, version 21.0 (Chicago,
USA).
Results
Patient characteristics
Table 1 summarizes the characteristics of the 121 patients
involved in our study. The majority of the study participants were
male (86.8%). The median patient age was 53 (37–78) years, and
90.9% of the patients were less than 65 years old. Major risk
factors such as tobacco and high daily alcohol consumption were
also observed. The primary tumor sites were the oropharynx
(18.3%), hypopharynx (20.8%), larynx (25%) and oral cavity
(31.7%). Locally regional tumors were predominant (52.3%), and
histologic types were well differentiated (32.5%), moderately
differentiated (35%), and poorly differentiated (32.5%). Cisplatin
was the preferred platinum therapy used (57.8%).
Treatment response rates
Table 2 and Table 3 summarize data on the ORRs assessed
after 3 and 6 cycles of platinum, 5-FU and cetuximab and
cetuximab maintenance treatment. Furthermore, Table 3 shows
the specific ORR among platinum options used in the protocol:
cisplatin versus carboplatin. The median duration of disease
control was 11 (0–115) weeks and accounted for 48.91% of
patients assessed. A complete response was observed in 6 patients
(6.5%), and a partial response was observed in 16 patients (17.4%).
Stable disease was observed in 23 patients (25%), and disease
progression occurred in 47 patients (51.08%). The median
Cetuximab+PF for Advanced HNSCC
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duration of maintenance treatment with cetuximab was 17 (0–85)
weeks. There were no statistical differences found for ORR with
respect to the platinum option used for the PF+ cetuximab
protocol. However, a trend towards improved outcomes in the
cisplatin group was noted (Table 3).
Safety and tolerability
The worst grade 3 and grade 4 adverse events (AEs) for patients
who were treated with the PF+ cetuximab protocol and for
patients who received cetuximab maintenance treatment are
reported in Table 4. Among the patients treated with the
cisplatin/5FU+ cetuximab regimen, the most commonly reported
AEs were febrile neutropenia (6.8%), neutropenia (6.8%), hypo-
magnesemia (3.4%), mucositis (1.7%) and pneumonia (1.7%).
Among patients treated with the carboplatin/5FU+ cetuximab
regimen, the most commonly reported AEs were skin rash (8.7%),
mucositis (6.5%), febrile neutropenia (4.3%), pneumonia (4.3%),
anemia (3.5%) and hypomagnesemia (2.2%). With respect to
cetuximab maintenance, skin rash was noteworthy (6.4%) among
patients treated in our cohort.
Outcomes: progression-free-survival and overall survival
Figure 1 and Figure 2 show the outcomes for PFS and OS. The
mortality rate was 86.3% during this retrospective cohort
assessment. The median follow-up period was 24 months.
Figure 1A shows PFS of all 121 patients involved in this study,
including those treated both with cisplatin, 5-FU, cetuximab or
carboplatin, 5-FU and cetuximab. The PFS was 8 months (95%
confidential interval (CI), 6.051–9.949). Figure 1B provides data
regarding platinum stratification sub-group PFS (cisplatin versus
carboplatin): 8 (95%CI, 6.002–9.998) versus 8 (95% CI, 1.754–
14.246) months, p= 0.968. Figure 2A shows the OS of all patients
Table 1. Characteristics of patients treated with platinum in
combination with 5-FU plus cetuximab.
No. %
No. of patients 121
Male 105 86.8
Age (years) 53 (37–78)
,65 years 110 90.9
$65 years 11 9.1
ECOG PS
0 4/103 3.9
1 83/103 80.6
2 13/103 12.6
3 3/103 2.9
4 0 0
Missing data 18 -
Tobacco use
Smoker 70/91 76.1
Ex-smoker 10/91 10.9
Never-smoker 11/91 12
Missing data 30 -
Alcohol
$60 g/day 74/86 86.04
,60 g/day 12/86 13.95
Missing data 35
Primary tumor site
Oropharynx 22/120 18.3
Hypopharynx 25/120 20.8
Larynx 30/120 25
Oral Cavity 38/120 31.7
Others 5/120 4.2
Missing data 1 -
Extent of diseasse
Only locoregionally 56/106 52.8
Metastatic/local recurrence 50/106 47.2
Missing data 15 -
Histologic grade
Well differentiated 13/40 32.5
Moderately differentiated 14/40 35
Poorly differentiated 13/40 32.5
Not specified 11 -
Missing data 70 -
Platinum
Cisplatin 63/109 57.8
Carboplatin 46/109 42.2
Missing data 12 -
Previous treatment
Chemotherapy 28/108 25.9
Radiotherapy 25/108 23.1
Chemo-radiotherapy 35/108 32.4
Missing data 13 -
CENSOR
No. deaths 88 86.3
Abbreviations: ECOG PS, eastern cooperative oncology group performance
status; 5-FU, 5-fluourouracil.
doi:10.1371/journal.pone.0086697.t001
Table 2. Treatment characteristics after 3 or 6 cycles of
platinum, 5-fluourouracil and cetuximab.
No. %
Patients enrolled 121 -
PF+ cetuximab
Complete response 6/92 6.52
Partial response 16/92 17.39
Stable disease 23/92 25
Progression or without response 47/92 51.08
Missing data+ 29 -
Overall response rate (ORR)* 22/92 23.91
Disease control** 45/92 48.91
Duration of ORR (weeks)*** 11 (0–115)
Cetuximab maintenance
No response 38/45 84.4
Stable disease 7/45 15.6
Without maintenance 47 -
Missing data 29 -
Duration of maintenance (weeks) 17 (0–85)
Abbreviations: PF, platinum (cisplatin or carboplatin) and 5-fluourouracil.
+Include patients who have not image assessment before cycle 3 due to
toxicities issues.
*ORR refers to overall response rate and includes complete response and partial
response, according to RECIST criteria.
***ORR+stable disease.
**Median.
doi:10.1371/journal.pone.0086697.t002
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treated with platinum (cisplatin or carboplatin), 5-FU and
cetuximab. The OS was 11 months (95%CI, 8.684–13.316). In
addition to these results, Figure 2B shows the OS of sub-groups
stratified by platinum treatment (cisplatin versus carboplatin). The
OS was 12 months for cisplatin (9.460–14.540) versus 8 months
(3.808–12.192) for carbolatin, p = 0.034.
Discussion
The treatment of advanced SCCHN is still a challenge for
surgeons, radio-oncologists and medical oncologists worldwide. A
multidisciplinary schedule should be established in all cases to
provide optimized approaches [4]. In recurrent and/or metastatic
disease, systemic treatments have had a major role in improving
survival and quality of life [16]. In 2008, a major advance in
SCCHC treatment was provided with the addition of cetuximab
to platinum and 5-FU chemotherapy [3]. Other trials have
attempted to assess alternative choices for controlling metastatic
disease, such as erlotinib, lapatinib, afatinib, rilotumumab,
ficlatuziumab and ornatuzumab, but the data are preliminary
[18–20]. This retrospective study was very important because it
Table 3. Treatment characteristics according to platinum used for CF+ cetuximab.
Cisplatin (%) Carboplatin (%) p value
Patients enrolled 53 (57.6) 39 (42.4)
Age (years)** 53 (37–78) 57 (37–75) 0.024***
PF+ cetuximab
Complete response 3/53 (5.7) 3/39 (7.7)
Partial response 13/53 (24.5) 3/39 (7.7) 0.216*
Stable disease 12/53 (22.6) 11/39 (28.2)
Progression or without response 25/53 (47.2) 22/39 (56.4)
ORR+ 16/53 (30.2) 6/39 (15.4) 0.258*
Disease control rate++ 28/53 (52.8) 17/39 (43.6) 0.381*
Duration of ORR (weeks)** 11.5 (0–115) 11 (0–91) 0.427***
Cetuximab maintenance
No response 24/26 (92.3) 14/19 (73.7)
Stable disease 2/26 (7.7) 5/19 (26.3) 0.089*
Duration of maintenance (weeks)** 18 (0–58) 15 (3–85) 0.780***
Abbreviations: PF, platinum (cisplatin or carboplatin) and 5-fluourouracil.
+ORR refers to overall response rate and includes complete response and partial response.
++Disease control rate includes complete response, partial response and stable disease.
*Qui square test.
**Median.
***Mann-Whitney U Test.
doi:10.1371/journal.pone.0086697.t003
Table 4. Grade 3 and/or grade 4 adverse effects observed according to CTCAE version 4.0.
PF+ cetuximab Cisplatin +5FU+cetuximab
Carbooplatin
+5FU+cetuximab Cetuximab
No. % No. % No. % No. %
Febrile 6 5.7 4 6.8 2 4.3 1 0.9
Neutropenia 5 4.7 4 6.8 1 2.2 0 -
Skin rash 4 3.8 0 - 4 8.7 7 6.4
Mucositis 4 3.8 1 1.7 3 6.5 1 0.9
Anemia 3 2.8 0 - 3 3.5 0 -
Hypomagnesemia 3 2.8 2 3.4 1 2.2 0 -
Pneumonia 3 2.8 1 1.7 2 4.3 0 -
Dispneia 0 - 0 - 0 - 1 0.9
Sepsis 1 0.9 1 1.7 0 - 0 -
Infusion reactions 1 0.9 1 1.7 0 - 0 -
Vomiting 1 0.9 1 1.7 0 - 0 -
Low platelet count 1 0.9 1 1.7 0 - 0 -
Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events. 5FU, 5-fluourouracil.
doi:10.1371/journal.pone.0086697.t004
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assessed the role of cetuximab in association with platinum-
fluoropirimide chemotherapy for SCCHN in a southern European
comprehensive cancer institution. In this study, 121 patients
treated with this regimen were assessed, and the outcomes were
similar to those of the EXTREME trial conducted by Vermoken et
al. [3] that led to the approval of this regimen. Vermoken’s study
assessed 222 recurrent/advanced SCCHN patients who under-
went screening at 81 centers in 17 European countries. Cisplatin
was administered as the initial platinum-based treatment in 149
(67%) patients. The median OS was 10.1 (95% CI, 8.6–11.2)
months, and the median PFS was 5.6 (95% CI, 5.0–6.0) months.
The ORR was 36% in that patient group. Although our
retrospective study was performed in only one European center,
the sample size was large (121 patients) and included approx-
imately half of the total number of patients involved in the
EXTREME trial. Thus, the analysis described herein provides
valuable data regarding what actually occurs outside of a clinical
trial. The results were quite similar to those first presented in the
literature despite a small trend toward an improved disease control
rate (48.9%), PFS (8 months) and OS (11 months). This result may
be explained by ethnic differences among the study populations.
Our study used a predominantly Portuguese population, and a
Figure 1. Show PFS of all patient treated with platinum +5-FU +cetuximab (A); and stratified by platinum (B): carboplatin +5-
FU+cetuximab versus cisplatin +5-FU+cetuximab. Analysis was performed using log-rank test. Abbreviations: PFS stands for progression-free-
survival; C stands for platinum (carboplatin or cisplatin); 5-FU stands for 5-fluourouracil.
doi:10.1371/journal.pone.0086697.g001
Figure 2. Show OS survival of all patients treated with platinum +5-FU+cetuximab (A); and stratified by platinum (B): carboplatin
+5-FU+cetuximab versus cisplatin +5-FU+cetuximab. Analysis was performed using log-rank test. Abbreviations: OS stands for overall-survival;
C stands for platinum (carboplatin or cisplatin); 5-FU stands for 5-fluourouracil.
doi:10.1371/journal.pone.0086697.g002
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heterogeneous European population was involved in the EX-
TREME trial [15,21–24]. In addition, SCCHN tumors are rich in
EGFR, which may explain the high sensitivity to anti-EGFR
therapies [25]. Previous studies have shown that epidermal growth
factor (EGF) +61 A/G polymorphisms are associated with cancer
susceptibility and EGF tumor expression [26]. In Portugal, several
studies have assessed the role of epidermal growth factor and its
receptor regulation with respect to cancer susceptibility for gliomas
[27], gastric cancer [28] and lung cancer [22]. Therefore, we
hypothesize that tumors of epithelial origin exhibit high EGF
expression in the Portuguese population and that these tumors are
more sensitive to anti-EGFR agents such as cetuximab. However,
further studies assessing EGFR expression in tumor tissue should
be performed to validate our hypothesis. In addition, the majority
of patients (57.8%) received cisplatin-based regimens that were
associated with improved OS compared to carboplatin-based
regimens: 12 (95%, CI, 9.46–14.54) versus 8 (95%, CI, 3.308–
12.192) months, p= 0.034. The results of this study also confirm
the superior sensitivity of cisplatin-based regimens in association
with cetuximab compared to carboplatin-based regimens that
were previously reported in the literature [9]. Carboplatin-based
regimens are reserved for patients who may not tolerate cisplatin
because of poor ECOG status or other co-morbidities, such as
diabetes (with neuropathy) or previous stage I–III renal failure
[29]. In addition to these results, the toxicity profile presented was
very acceptable and controlled among patients treated in this
cohort. The rate of febrile neutropenia was lower than that
reported in the EXTREME trial for PF+ cetuximab (5.7% versus
22%). This result may be explained by the previous treatment with
routine prophylactic antibiotic-therapy with ciprofloxacin and G-
CSF (granulocytic and colony stimulate factor) that the patients
received [30–32]. The patients experienced fewer grade 3 or grade
4 AEs than the patients involved in the EXTREME trial [3]: skin
rash, 3.8 versus 9%; anemia, 2.8% versus 13%; thrombocytope-
nia, 0.9 versus 11%; hypomagnesemia, 2.8 versus 5%; pneumonia,
2.8% versus 4%; sepsis, 0.9% versus 4%; vomiting, 0.9% versus
5%, respectively (table 4). However, the patients experienced more
mucositis grade 3 or 4 events (3.8%) than previously reported for
the PF+ cetuximab regimen [3]. The regimen toxicity profile could
be more uniform and could be better managed in a single
European comprehensive institution study than in a multi-center
study that involved 81 centers in 17 different European countries.
The chemotherapy supportive care to control emesis [33–35],
hematologic effects [30,36–38] and infections [30,32] would
depend on different local protocols, populations, environmental
exposures and public health conditions. For patients with
recurrent/metastatic disease and low but adequate fitness perfor-
mance status, other options such as cetuximab and placlitaxel [10],
cetuximab and bevacizumab [39], oxaliplatin, infusional-5-FU
and cetuximab [12] have been studied and showed promising
results. In 2012, Hitt et al. [10] published the results of a phase II
study that assessed 46 advanced SCCHN patients who received
paclitaxel 80 mg/m2 and cetuximab 400/250 mg/m2 weekly until
disease progression or unacceptable toxicity. The ORR was 54%
(95% CI, 39–69%), and the PFS was 4.2 (95% CI, 2.9–5.5)
months. The OS was shown to be 8.1 (95% CI, 6.6–9.6) months.
The most common grade 3 or 4 AEs were skin rash (24%),
asthenia (17%) and neutropenia (13%). The authors concluded
that this regimen is safe and well-tolerated and had promising
outcomes for medically unfit patients and patients for whom
platinum is contraindicated. In 2013, Argiris et al. [39] reported
the results of another phase II trial enrolling 46 advanced SCCHN
patients who received weekly cetuximab 400/250 mg/m2 and
bevacizumab 15 mg/m2 on day 1 given intravenously every 21
days until disease progression or the occurrence of unacceptable
AEs. The ORR was 16%, the PFS was 2.8 months, and the OS
was 7.5 months. The most common grade 3 or 4 AEs occurred in
less than 10% of all patients. Despite these modest results, several
phase III studies are still required to determine the role of
biological agent combinations in this patient population.
Conclusions
The combination of anti-EGFR therapies with platinum-based
chemotherapy is a cornerstone in the new era of SCCHN
treatment. Over the last 30 years, there have been no significant
innovations concerning systemic treatment for recurrent/meta-
static disease. Cetuximab has emerged as a key player in the
treatment of SCCHN patients in association with platinum and 5-
FU. To the best of our knowledge, our retrospective study is the
first to report on the medical experience of this regimen in a
relatively large southern European Portuguese population. Fur-
thermore, we confirmed that the results were in agreement with
the literature. Thus, the cisplatin-based PF+ cetuximab regimen is
a good option for systemic treatment in medically fit advanced
SSCHN patients. Moreover, the treatment has a well-tolerated
toxicity profile. Further studies are warranted to determine
biomarkers for personalizing therapies and improving outcomes
in this set of patients.
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